Dr. Reddy’s may choose to license toripalimab in New Zealand, Australia, as well...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
The pharmaceutical industry continues to be a hotbed of innovation, with activit...
“You can't make an asymptomatic person feel better," cardiologist Rita Redberg s...
Using a unique AI tool, built from a half-dozen other algorithms, Every Cure is ...
In the latest edition of STAT's Health Tech newsletter: Vinod Khosla's bold AI p...
The Phase II clinical trial will assess the efficacy and safety of PBF-999 in re...
Dupixent’s worldwide net sales increased by 37% to $2.49bn Q1 to Q1 2022-23.
The UK government opens negotiations with industry and NHS representatives to cr...
Pharmaceutical firms face a daunting but unavoidable challenge of creating digit...
NIEHS and TFF will assess the TFF-HMW-HA formulations’ therapeutic efficacy and ...
Dupixent was initially approved to treat moderate-to-severe atopic dermatitis in...
